RxDoctor Payments Data

Geralyn Ponzio, MD

Internal Medicine · Montclair, NJNPI 1962484501

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 37 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$240
  • Amgen$157
  • Dexcom, Inc.$150
  • Radius Health, Inc.$125
  • Johnson & Johnson$93
  • Abbott$77
  • plus $203 from 5 others

What the payments were for

  • Food & beverage$1,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$408,563
Medicare patients
785
Services billed
7,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide132$166,600
OzempicSemaglutide72$92,893
TrulicityDulaglutide56$69,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$51,822
EliquisApixaban51$46,018
JardianceEmpagliflozin28$41,409
WegovySemaglutide12$34,865
FarxigaDapagliflozin Propanediol21$23,636
JanuviaSitagliptin Phosphate15$20,475
RybelsusSemaglutide11$16,638
Breo ElliptaFluticasone/Vilanterol27$15,970
MyrbetriqMirabegron27$15,742
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$12,909
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$7,638
Novolog FlexpenInsulin Aspart29$5,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$240$144,39695 claims
PfizerEliquis$38$46,01851 claims
Boehringer IngelheimJardiance$24$41,40928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Montclair

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →